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Hematopoietic stem cell transplantation (HSCT) is a potentially life-saving therapy that has traditionally been
associated with high treatment-related mortality due to direct regimen toxicity and a high incidence of graft-
versus-host disease. Historically, pre-existing renal insufﬁciency has been considered an exclusion criterion
for transplantation. The advent of nonmyeloablative conditioning regimens as a less toxic modality for
treatment has made HSCT more accessible to elderly patients and patients with comorbidities, such as renal
impairment. However, there is no clear standard for how to dose preparative regimens for patients with
chronic renal impairment who undergo HSCT. This article serves as a review of the current literature to
provide dosing recommendations for commonly used preparative agents in the setting of chronic kidney
disease, with the aim of providing optimal dosing for this patient population.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is
considered to be a life-saving therapy for patients with
certain malignant and nonmalignant disease states. It has
been well documented in the literature that renal injury is a
common complication of HSCT and leads to increased
morbidity and mortality [1-4]. Patients with pre-existing
chronic kidney disease (CKD) are frequently not considered
to be candidates for HSCT and are, therefore, not offered this
potentially life-saving therapy. Additionally, major risk
scoring indices include renal insufﬁciency as a risk factor for
post-transplantation mortality [5,6].
There have been various reports in the literature
describing successful autologous and allogeneic HSCT for
patients with CKD, including patients with end-stage renal
disease (ESRD) requiring dialysis. However, the literature
consists of mostly case reports and small case series, and
there is no clear consensus on optimal dosing for preparative
regimens before transplantation. When selecting a prepara-
tive regimen for patients with CKD who undergo trans-
plantation, there is always a risk for unintentional
overdosing or underdosing, based on variable pharmacoki-
netics in this patient population. Underdosing may lead to
graft rejection or suboptimal disease control, whereas over-
dosing may lead to multiorgan toxicity [7].edgments on page 909.
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A thorough review of the MEDLINE library database with review of
supporting references of included and excluded articles was performed. The
literature search was limited to articles published in English with human
participants (Appendix 1). MESH headings and key words searched were
renal insufﬁciency, chronic; kidney failure, chronic; bone marrow trans-
plantation; and hematopoietic stem cell transplantation.RESULTS
It was found that the available literature provides insuf-
ﬁcient information to draw evidence-based conclusions
(level I or II) upon how to optimally dose a HSCT preparative
regimen in a patient with baseline renal impairment. This
was due to the largely retrospective nature of the reports,
limited information regarding creatinine clearance and
dialysis schedules for patients who were hemodialysis
dependent, and lack of pharmacokinetic reporting for the
majority of cases. The available data are supportive of HSCT
in patients with renal insufﬁciency, but the data are insufﬁ-
cient to provide optimal dosing regimens for patients with
renal impairment. This is especially true in pediatric patients
because of the differences in pharmacokinetic parameters
and more limited reported data.
Because of the limitations encountered during this re-
view, and the inability to develop level I or II recommenda-
tions, it was decided to instead provide a summary of the
published literature. The research question of what prepar-
ative regimenmay yield the best outcomes for these patients
has evolved into a guideline to provide a basis for future
studies of these patients. With that intent, the following in-
formation on preparative regimens in HSCT patients is re-
ported to set a basis for regimen selection, especially aimedSociety for Blood and Marrow Transplantation.
Table 1
Dosing Recommendation for Agents in Hematopoietic Stem Cell Transplantation
Agent Suggested Dosing Additional Information
Alemtuzumab Unmodiﬁed This agent has not been studied in the setting of renal
impairment. Available literature suggests no adjustment
is required in the setting of insufﬁciency.
Antithymocyte globulin
(equine)
Unmodiﬁed This agent has not been speciﬁcally studied in the setting
of renal impairment; however, elimination does not appear
to be inﬂuenced by renal function.
Antithymocyte globulin
(rabbit)
Unmodiﬁed This agent has not been speciﬁcally studied in the setting of
renal impairment; however, elimination does not appear to
be inﬂuenced by renal function.
Busulfan Unmodiﬁed Renal excretion plays a minor role in elimination for patients
who receive this agent, even in the setting of dialysis.
Clofarabine Avoid use in adults > 60 yr with creatinine
clearance <60 mL/min (NCCN AML guidelines)8
Fifty percent dosage adjustment with CrCl 30
to 60 mL/min9
Primarily excreted by the kidney, with 60% of the drug being
excreted unchanged by both tubular secretion and glomerular
ﬁltration, with a half-life of 4-6 h in most cases. Administration
may be possible for patients on hemodialysis.
Cyclophosphamide Unmodiﬁed in the setting of mild renal
impairment.
Consider dosage reduction in the setting of
moderate to severe renal impairment.
Moderately dialyzable (20%-50%); for patients who are
dialysis dependent, administer dose after hemodialysis.
Increased myocardial toxicity observed in CKD patients.
Pharmacokinetic studies have demonstrated decreased
clearance with renal insufﬁciency.
Fludarabine 20%-25% dose reduction in the setting of
mild-to-moderate renal impairment.
50% dosage adjustment in the setting of severe
renal impairment or in the setting of hemodialysis.
Sixty percent of the active metabolite 2-ﬂuoro-ara-A (F-ARA-A)
is cleared renally.
Melphalan 100-140 mg/m2 for patients with renal
impairment and those who are dialysis
dependent
Melphalan is apparently not removed by dialysis, but the short
half-life in water may contribute to the lack of detectable levels
in the dialysate. Sixty percent is bound to plasma proteins,
primarily albumin. Prolonged mucositis has been observed with
standard doses in CKD patients.
Rituximab Unmodiﬁed This agent has not been studied in the setting of renal
impairment. Available literature suggests no adjustment is
required in the setting of insufﬁciency.
Thiotepa Unmodiﬁed in the setting of mild-to-moderate
renal impairment.
Cleared through liver metabolism and not affected by renal
function. May be contraindicated in the setting of severe
renal dysfunction.
NCCN indicates National Comprehensive Cancer Network; AML, acute myelogenous leukemia; CKD, chronic kidney disease; CrCl, creatinine clearance.
M.N. Bodge et al. / Biol Blood Marrow Transplant 20 (2014) 908e919 909at supporting the study of drug dosing in patients with
baseline impaired renal function. In Appendix 2, the data
available for dosing in patients with baseline renal impair-
ment will be reported, in addition to general population re-
sults and sufﬁcient supporting information, such that the
medical provider can assess the applicability to their
respective patient populations.CONCLUSIONS
High-dose chemotherapy followed by HSCT is becoming
more widely utilized in patients with comorbidities,
including those with renal insufﬁciency. It is often assumed
that pharmacokinetics and pharmacodynamics of prepara-
tive regimen agents are signiﬁcantly altered in the setting of
renal insufﬁciency; however, this review suggests that HSCT
can be safely performed in patients with baseline renal
impairment. Based upon this literature review, recommen-
dations for dosing chemotherapeutic agents in HSCT condi-
tioning regimens are provided (Table 1). Please note the
standardized deﬁnitions to support clarity in providing
dosing information. Furthermore, to support patient care, we
suggest future research that pertains to the dosing of anti-
neoplastics or toxicity assessment in conditioning regimens
for HSCT be required to report patient baseline renal
impairment and assess patient outcome and toxicity with
reference to these parameters.ACKNOWLEDGMENTS
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Appendix 1
Renal Impairment Overviews and Recommendations
Reference Basis Comments Outcomes Recommendation
[10] Prospective study to evaluate the relationship
between Mel pharmacokinetics and renal
function in 20 patients with multiple myeloma.
All patients received 200 mg/m2 Mel divided
into 2 daily doses of 100 mg/m2 i.v. on 2
consecutive days, followed by peripheral
blood stem cells.
Six patients had severe renal insufﬁciency
(CrCl <40 mL/min), including 5 patients on chronic
hemodialysis.
Mel pharmacokinetics, performed after the ﬁrst dose
of 100 mg/m2, was not adversely affected by impaired
renal function. Renal insufﬁciency did not have an
apparent negative impact on stem cell collections or
adversely affect post-transplantation engraftment,
transfusion requirements, incidence of severe mucositis, or
overall survival. It was associated with longer durations
of fever (P ¼ .0005) and hospitalization (P ¼ .004).
Renal failure does not require
dose reduction of Mel in auto
transplantation.
[11] Report of 6 patients with multiple myeloma
and chronic renal insufﬁciency, including 4
on dialysis, who received high-dose BuCy,
followed by auto stem cell transplantation.
No dose adjustments were made for renal
failure in the BuCy prep regimen. Bu was
given at 1 mg/kg PO every 6 h for 16 doses
and Cy was given at 60 mg/kg/d i.v.  2 d.
Chronic renal insufﬁciency deﬁned as serum
creatinine >3.0 mg/dL. All patients on dialysis
had renal biopsies; 2 demonstrated light chain
deposition disease and the other 2 demonstrated
myeloma cast nephropathy. Patients requiring
renal replacement therapy were dialyzed before
the ﬁrst dose of Cy and again at 24 and 48 h after
completion of the second dose.
Patterns of engraftment and toxicities were not apparently
different from those seen in myeloma patients with normal
renal function. There was 1 toxicity-related death, 1 patient
died from disease progression 6 mo after transplantation,
and the remaining 4 are alive and free of myeloma
progression 6-39 mo after HDT.
BuCy is an acceptable preparative
regimen in patients with multiple
myeloma and CKD.
[12] Case report of a 31-yr-old patient with CML
who developed malignant nephrosclerosis
with renal failure. He underwent an allo-HSCT
in ﬁrst chronic phase CML with a preparative
regimen consisting of TBI with a total dose of
13.5 Gy from d 6 to 4 and Cy 60 mg/kg once
daily i.v. on d 3 and 2. The pharmacokinetics
of Cy on hemodialysis were studied. Clinical
parameters were compared with those of a
patient with normal renal function who also
received an unrelated HSCT as treatment for
CML in ﬁrst chronic phase.
Hemodialysis was performed 6 h after each Cy
dose over a period of 6 h. The patient also received
bladder irrigation and a continuous i.v. infusion of
mesna 60 mg/kg/24 h on d 3 and 2. GVHD
prophylaxis consisted of cyclosporine and prednisone.
Patient B also received methotrexate 15 mg/kg on
d þ1 and 10 mg/kg on d þ3 and þ6.
Drug-related toxicity was similar in both patients. Both
patients developed grade II mucositis, grade II
gastrointestinal toxicity, and only mild hepatic
dysfunction. No difference was seen in time to
engraftment. Peak Cy concentration on d 1 was 303.0
mmoL/L for patient A and 397.7 mmoL/L for patient B.
Cy/TBI is a suitable conditioning
regimen for allo-HSCT in patients
with renal failure on hemodialysis.
[13] A patient with pre-existing ESRD underwent
successful matched related donor allo bone
marrow transplantation using conditioning
with high-dose Cy (60 mg/kg/d  2) and
TBI (165 cGy twice daily  4 d)
Six-h hemodialysis sessions were performed
before CY infusion and again 14 h after the end
of each of the 2-h CY infusions on d 6 and 5.
Regular 4-h hemodialysis sessions were resumed
on d 4, then 3 times weekly until hospital discharge.
Systemic clearance in this patient was 38.4 mL/min,
compared with the normal range of 51-100 mL/min
in patients with normal renal function.
The patient’s clinical course was uncomplicated. There
were no acute cardiac effects detected or hemorrhagic
cystitis. He did develop CMV infection on d þ46 with
positive blood and urine cultures, which was cleared
following a 14-d course of ganciclovir therapy. He
developed mild chronic GVHD 6 mo after
transplantation after discontinuation of prophylactive
prednisone.
Cy/TBI is a feasible preparative
regimen for patients with ESRD.
[14] Report of 6 patients with multiple myeloma
and moderate-to-severe renal insufﬁciency
who were treated with auto stem cell
transplantation. Preparative regimens
included Bu 12 mg/kg þ Mel 120 mg/m2
(4 patients) or a single dose of Mel 80 mg/2
alone for a patient with CrCl <20 mL/h and
the patient on hemodialysis.
Impaired renal function was deﬁned by CrCl <40 mL/h.
Five patients had renal failure at the time of diagnosis
(median, CrCl 27 mL/h; range 5-34 mL/h). Renal biopsy
revealed a picture of myeloma-cast nephropathy in 3
patients or light-chain deposition in 2 patients. One
patient had severe renal insufﬁciency, which required
hemodialysis 3 times per wk. The patient on
hemodialysis who received Mel 80 mg/m2 had
hemodialysis performed 2 h after Mel infusion.
Engraftment occurred in all patients after
transplantation. Three patients experienced grade
3-4 mucositis and 1 patient experienced veno-occlusive
disease. Renal function either improved or remained
stable throughout the transplantation period.
Bu and Mel are acceptable
preparative agents for patients
with moderate-to-severe renal
insufﬁciency.
[15] Case report detailing the impact of
hemodialysis on the clearance of Bu in a
patient with chronic renal failure undergoing
auto peripheral stem cell transplantation.
The patient received 5 test doses (.17 mg/kg)
and 14 therapeutic doses (.60-1.0 mg/kg) of oral
Bu given every 6 h over 5 d, followed by 2 daily
infusions of Cy (100 and 50 mg/kg). Bu doses were
administered at the start of a 4-h hemodialysis session.
The extraction ratio for Bu across the dialyzer was
.530  .026 at a blood ﬂow of 400 mL/min, which
corresponds to a hemodialysis clearance of 2.23  .56
mL/min/kg. A 4-h hemodialysis session enhanced the
apparent oral clearance of Bu by 65%.
Plasma Bu concentration
monitoring is warranted in
patients undergoing hemodialysis.
(continued on next page)
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Appendix 1
(continued )
Reference Basis Comments Outcomes Recommendation
[16] Report of 81 multiple myeloma patients with
renal failure at the time of auto HSCT,
including 38 patients on dialysis. Sixty patients
(27 on dialysis) received Mel 200 mg/m2
(Mel-200) given as 100 mg/m2 for 2 d. Due to
excessive toxicity, the subsequent 21 patients
(11 on dialysis) received Mel 140 mg/m2.
Thirty-one patients, including 11 on dialysis,
completed tandem auto-HSCT.
Renal failure was deﬁned as creatinine >176.8 mmoL/L.
Patients on dialysis who received Mel were dialyzed
before Mel infusions and again 24-48 h after stem
cell infusion. Renal failure patients tend to have a low
serum albumin, which may affect Mel
pharmacokinetics, as 60% of the drug is bound
to plasma proteins, primarily albumin.
Median times to neutrophil and platelet engraftment
were 11 and 41 d, respectively. Nonhematologic
toxicities included mucositis, pneumonitis, dysrhythmias,
and encephalopathy. At a median follow-up of 31 mo,
30 patients had died. Complete remission was achieved
in 21 patients after ﬁrst HSCT and 31 patients after
tandem HSCT. Dialysis dependence and Mel dose did
not affect event-free or overall survival.
Mel 140 mg/m2 had an acceptable
toxicity and appears equally
effective when compared with
Mel-200. Renal failure patients
with low albumin and higher TRM
may do better with even lower
doses of Mel (70-100 mg/m2)
[17] Case report of a 4.5-yr-old boy with FA and
CKD who underwent successful allo-HSCT.
His conditioning regimen consisted of
Cy 20 mg/kg þ TAI 500 cGY.
GVHD prophylaxis consisted of Cy. The patient successfully engrafted and did not develop
GVHD. His kidney function did continue to decline to
dialysis dependence 2 y after bone marrow
transplantation. Three and one half years after his HSCT,
the patient received a renal transplant and his serum
creatinine normalized.
CY/TAI is an acceptable
preparative regimen for patients
with CKD.
[18] Case report detailing the course of a 27-yr-old
man with AA and renal insufﬁciency requiring
dialysis who underwent allo-HSCT. The patient
had ESRD, which predated his bone marrow
failure by 15 yr. The patient’s preparative regimen
consisted of Mel 60 mg/m2, ATG (equine) 15
mg/kg  3 d, and TLI 4.0 Gy in 2 fractions for 1 d.
Before transplantation, serum levels of creatinine
and BUN were 990 mmoL/L and 43.5 mmoL/L. The
patient was dialyzed before Mel administration
and again 24 and 72 h after administration. GVHD
prophylaxis consisted of cyclosporine and
prednisolone.
The patient’s clinical course was uncomplicated. He
experienced rapid engraftment and pharmacokinetic
parameters of Mel were not signiﬁcantly altered. The
patient developed grade I mucositis and did not develop
veno-occlusive disease. Pharmacokinetic parameters for
Mel were Cmax 5.3 mg/L, elimination t1/2 of 98.1 min,
AUC 7.65 mg h/L, Vc 6.3 l/m2, Vdss 15.6 l/m2, CLs .126
L/min m2.
Mel can be safely used in
patients with renal failure
requiring dialysis.
[19] Prospective study of 22 patients with varying
levels of renal function who received a single i.v.
dose of Flu (25 mg/m2) followed 1 wk later by 5
(1 per d) doses that were adjusted according
to 3 predeﬁned CrCl levels.
Sixty percent of Flu’s primary metabolite (F-ara-A)
is eliminated renally.
Total F-ara-A clearance correlates with CrCl and F-ara-A
exposure levels and patient toxicity proﬁles were similar
across treatment groups.
Flu is an acceptable preparative
agent for patients with renal
insufﬁciency with dose
adjustment.
[20] Analysis of 59 dialysis-dependent patients who
received high-dose Mel before auto transplantation.
The ﬁrst 27 patients received Mel 200 mg/m2 as a
single agent 2 d before transplantation. The dose
was subsequently reduced to 140 mg/m2 (n ¼ 32)
because of signiﬁcant toxicity.
37 patients had been on dialysis  6 mo. Stem cell
transplantation was preceded by dialysis 24-36 h
after Mel.
Five-year event-free and overall survival rate of all
patients after HSCT were 24% and 36%, respectively.
Of 54 patients who were evaluable for renal function
improvement, 13 became dialysis independent at a
median of 4 mo after HSCT (range, 1-16). Twenty-three
patients received a second auto-HSCT; of women, 4
died of TRM during the 6 mo after second HSCT.
Mel 140 mg/m2 is less
toxic than 200 mg/m2.
[21] Report of a patient with anuric acute renal failure
who received Flu 40 mg/m2 twice daily for 3
consecutive days.
The patient underwent 3 consecutive extended
(daily) dialysis sessions, which removed a
considerable amount of the drug.
The average dialysis clearance was 33.85 mL/min, which
is about 25% of the clearance of a patient without renal
failure. No toxic side effects were observed.
Flu treatment may be considered
in dialysis patients if dose
reduction and adequate removal
by hemodialysis are provided.
[22] Trial of 137 patients who received high-dose
chemotherapy with auto transplantation at a
single center. Patients were divided into 3 groups
based on estimated CrCl. Group A had normal
renal function both at diagnosis and at
transplantation (n ¼ 78), group B had normal
renal function at transplantation (n ¼ 30), and
group C had renal failure both at diagnosis and
at transplantation (n ¼ 29). The majority of
patients received Mel 200 mg/m2. Eleven patients
received Mel 100 mg/m2 for 2 d, and 3 patients
received Mel 140 mg/m2 for 1 d.
Renal failure was deﬁned as CrCl <60 mL/min.
Estimated CrCl was calculated based on the CG
formula. Eight of the 29 patients in group C
were on hemodialysis at the time of transplantation.
There were no differences in the number of stem cells
harvested, time to engraftment, or response to
transplantation between the groups. Ten of the patients
in group C had normalization of renal function after
transplantation. Signiﬁcantly longer hospitalization,
increased use of blood products, and increased number
of infections were seen in group C compared with groups
A and B. TRM was 17% in group C compared with 0% and
1% in groups B and A, respectively. Four of the 8 patients
on dialysis at the time of transplantation died from TRM.
High-dose chemotherapy is
feasible in multiple myeloma
patients with renal failure.
Reduction to 140 mg/m2 or
100 mg/m2 for 2 d are potential
approaches to patients with renal
impairment.
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[23] Evaluated the toxicity and survival of
dialysis-dependent patients who underwent
HDT supported by auto stem-cell transplantation
with Mel 100 mg/m2 compared with those
without renal insufﬁciency (Mel 200 mg/m2) in
a matched pairs analysis of 34 patients.
Renal failure requiring dialysis occurred a median
of 4.5 mo (range, 1-8) before HSCT.
No signiﬁcant differences were observed between
hematologic toxicity, TRM, or disease response.
Dialysis patients showed comparable event-free
and overall survival. They required signiﬁcantly
extended intravenous antibiotic treatment and
longer hospitalization. Two patients recovered
from dialysis dependency 5 and 6 mo after ASCT.
Recommend a reduced dosage of
Mel (100 mg/m2), which appears
to be equally effective and less
toxic, in patients on chronic
dialysis.
[24] Report of 4 pediatric patients with normalized
GFR <60 mL/min/1.73 m2. These patients received
auto-HSCT preparative therapy for advanced and
recurrent solid tumors with escalating Mel,
ranging from 135-180 mg/m2, thiotepa 200
mg/m2 for 3 d, and vincristine 1 mg/m2  2 doses.
Two patients had Wilms’ tumor and 2 patients
had neuroblastoma.
None of the patients developed acute renal failure,
excess toxicities, or delayed engraftment.
It is feasible and safe to perform
HSCT in pediatric patients with
low GFR using Mel- and
thiotepa-based preparative
regimens.
[25] Case report of 2 adult sickle cell patients who
underwent Flu-based nonmyeloablative stem cell
transplantation from HLA-identical matched siblings.
One patient had ESRD and 1 did not.
Pharmacokinetics of the Flu metabolite F-Ara-A
was studied in the patient with ESRD and 2
additional patients with normal renal function.
Conditioning consisted of 200 cGy TBI followed
by Flu 24 mg/m2 and Cy 500 mg/m2 both given
daily for 4 d and alemtuzumab 100 mg given in
divided doses over 5 d for the patient with ESRD.
Nearly identical Flu drug exposure to patients
with normal renal function was achieved with
a 20% dose reduction followed by daily dialysis
for six h, 12 h after each Flu dose.
Severe neurotoxicity is the primary concern in
this patient population due to potential for high
levels of F-ara-A.
Both patients achieved full donor erythroid
chimerism, have normal blood counts, and are on
no immunosuppressive medications. Neither patient
developed acute GVHD or chronic GVHD. Four
months after transplantation, the patient with ESRD
developed symptomatic heart failure with moderate
left ventricular dilation, a small pericardial effusion,
and an ejection fraction of 35%. Cy toxicity was
likely the primary cause of the patient’s cardiac
pathology; however, cardiac iron deposition may
have been a contributing factor.
Flu-based nonmyeloablative stem
cell transplantation is feasible
for patients, even in the setting
of ESRD.
[26] Report of 3 cases of severe AA with signiﬁcant
renal impairment from databases at 2 tertiary
care centers. Patient 1 received a preparative
regimen of Cy 87.5 mg/kg and ATG with a
modiﬁed Cy dose for creatinine clearance.
Patient 2 received a conditioning regimen of Flu
30 mg/d  4 d (reduced 50%), Cy 300 mg/m2  4
d, and alemtuzumab 75 mg. Patient 3 received a
conditioning regimen of Flu 30 mg/d  4 d
(reduced 50%), CY 10 mg/kg  4 d, and
alemtuzumab 60 mg.
Two patients had end-stage renal impairment
secondary to immunoglobulin A nephropathy
before the diagnosis of AA. The other patient
developed cyclosporine-induced nephrotoxicity
related to prior immunosuppressive therapy.
Patient 1 had a more signiﬁcant degree of renal
impairment (CrCl 11 mL/min at BMT) compared
to patients 2 (CrCl 43 mL/min) and 3 (CrCl 20
mL/min) and was dialysis dependent before
transplantation. Patients 2 and 3 used a
calcinuerin-free GVHD prophylaxis regimen.
Patient 1 experienced signiﬁcant regimen-related
toxicity and died of multiorgan failure 7 mo after
transplantation. Patients 2 and 3 did not develop
any acute or chronic GVHD and were off all
immunosuppressants by 12 and 9 mo after
transplantation, respectively.
These cases suggest that BMT is
feasible in patients with severe AA
and signiﬁcant renal impairment
when a minimally intensive
conditioning regimen is utilized.
[27] Case report of a 5-yr-old girl with FA and a
pretransplantation creatinine clearance of 22
mL/min who underwent allo HSCT. The
conditioning regimen utilized was Flu 15
mg/m2 for 3 d and TAI 4 Gy once.
GVHD prophylaxis consisted of mycophenolate
mofetil and prednisone.
The post-transplantation period was uncomplicated.
She did not develop mucositis, acute GVHD, or
infection. Her renal function remained stable and
she engrafted on d þ37.
Flu/TAI is an acceptable preparative
regimen for patients with impaired
renal function.
[28] Report of 13 patients with a GFR
<60 mL/min/1.73 m2 (range, 35-59) as a single
comorbidity before HSCT. All patients received
nonmyeloablative HSCT with Flu (30 mg/m2/d
for 3 d) followed by TBI at 200 cGY or TBI of 200
cGY alone given in the tandem auto and allo HSCT.
ATG (rabbit) was given to recipients of a matched
unrelated donor or a single HLA-antigen
mismatched family donor HSCT.
Patients received GVHD prophylaxis consisting
of mycophenolate mofetil and cyclosporine.
Serum creatinine was noted at the day of HSCT
and renal function was assessed with the
simpliﬁed MDRD Study prediction equation
at the day of HSCT.
Seven patients (54%) experienced improvement or
stabilization to a GFR 60 mL/min/1.73 m2 at last
follow-up. Four patients (31%) developed CKD stage
3 (GFR <60 mL/min/1.73 m2) compared with 3
patients (12%) in the control group (P ¼ .039).
There was no difference in survival between cases
and controls, as well as no differences in
complications after HSCT, cyclosporine dose,
and trough levels.
Nonmyeloablative HSCT can be
safely offered to patients with
mildly reduced renal function.
(continued on next page)
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Appendix 1
(continued )
Reference Basis Comments Outcomes Recommendation
[29] Report on 8 yr of experience with a conditioning
regimen of Flu 30 mg/m2 daily for 3 d, Cy 750
mg/m2 daily for 3 d, and rituximab 375 mg/m2
for 1 d plus 1000 mg/m2 for 3 d before allo-HSCT.
Included 47 patients who received HLA ematched
hematopoietic cells from related (n ¼ 45) or unrelated
(n ¼ 2) donors. Tacrolimus and methotrexate were
used for GVHD prophylaxis. Patients with serum
creatinine  1.6 mg/dL were excluded.
All patients achieved CR with only 2 relapses.
Median follow-up was 60 mo (range, 19-94).
Estimated survival and progression-free survival
rates were 85% and 83%, respectively. Optimal
dose of rituximab not clearly deﬁned.
Effective nonmyeloablative regimen
should be explored in patients with
renal impairment due to reduced
TRM observed in patients with
normal renal function.
[30] Study of 141 patients with AML (n ¼ 131) or
MDS (n ¼ 10) who underwent allo transplantation
with Flu/Mel-based regimens. Flu dose consisted
of 25-30 mg/m2 for 4-5 d and Mel dose was
100-180 mg/m2. ATG was added for recipients
of unrelated or mismatched-related donor HCT.
The inﬂuence of the estimated GFR measured before
transplantation on outcomes was analyzed.
GFR was estimated by both the CG and the MDRD
equations using the creatinine value obtained
before starting chemotherapy. Most of the patients
with renal function impairment had it for at least
1 mo before transplantation. For the subgroup with
baseline <60 (MDRD), the median GFR was 56
(range, 39-77) and one half had a GFR < 60. By the
CG method, patients with baseline GFR < 60 had a
median GFR of 56 (range, 23-106); 75% had a GFR
< 60 1 mo before transplantation.
Estimated GFR was  90 for 45 (32%), 60-89 for
78 (55%), and < 60 for 18 (13%) patients by CG
and GFR was  90 for 45 (32%), 60-89 for 66 (47%),
and < 60 for 10 (7%) of patients by MDRD. There
were no differences in overall survival and NRM in
the 3 groups by any GFR estimation method. The
median GFR remained stable in the survivors
belonging to the subgroup of patients with a
baseline GFR < 60 at 100 d and 1 yr after
transplantation.
Mild-to-moderate decrease in GFR
was not associated with an increase
in NRM. Flu/Mel is not markedly
nephrotoxic and conclusions
found in this trial may not apply
to other conditioning regimens.
[31] Case report of a 69-yr-old dialysis patient who
underwent auto HSCT after conditioning with
adjusted doses of Flu 6 mg/m2/d for 4 d and Mel
100 mg/m2 on the ﬁfth day.
The patient had a low performance status going into
transplantation. A reduction of about 75% and one
third of the doses of Flu and Mel respectively, were
given.
After 16 mo, the patient was alive and in CR with
no changes in dialysis requirement.
Flu/Mel is feasible in patients with
dialysis-dependent renal failure
[32] Case report of a 2-yr-old girl with conﬁrmed FA
and chronic renal failure, who underwent a
matched-related donor stem cell transplantation.
She received a conditioning regimen of Cy 3.75
mg/kg/d i.v. for 4 d, Flu 15 mg/m2/d i.v. for 3 d,
and rabbit ATG 5 mg/kg/d i.v. for 4 d.
At the time of transplantation, the patient’s estimated
calculated CrCl was 17 mL/min per 1.73 m2. The CrCl
based on 24-h urine collection was 12 mL/min per
1.73 m2.
The patient engrafted on d þ14 and had platelet
engraftment on d þ65. Chimerism studies on
d þ28 showed 100% donor myeloid and lymphoid
engraftment. Her renal laboratory proﬁle remained
within the same pre-SCT range.
Flu and Cy are acceptable
preparative agents for patients
with renal insufﬁciency.
[33] Case report of a 61-yr-old man with ESRD who
had been on hemodialysis for 5 yr and underwent
allo-HSCT from a mismatched unrelated donor.
The conditioning regimen used was Flu 15 mg/m2/d
for 5 d, Mel 50 mg/m2/d for 2 d, and TBI (400 cGy).
ATG 1.25 mg/kg/d for 2 d was given before
transplantation for prophylaxis of acute GVHD.
During the conditioning regimen, daily hemodialysis
was performed for volume control. Tacrolimus and
mycophenolate mofetil were used for GVHD
prophylaxis.
The patient engrafted successfully at d 12 after
transplantation. Donor chimerism at d 29 revealed
100% donor cells. The patient developed sinusoidal
obstruction syndrome on d 12 and bilirubin
increased to 8.1 mg/dL. He also developed grade III
gut GVHD on d 15, which resolved with
methylprednisolone treatment.
Dose-adjusted Flu, Mel, and TBI
are sufﬁcient and tolerable
preparative regimens for allo-HSCT
in patients with ESRD requiring
hemodialysis.
[34] Case report of a 22-yr-old patient with refractory
ALL and ESRD requiring dialysis who was treated
with clofarabine 40 mg/m2/d for 5 d and cytarabine
20 mg/m2/d subcutaneous for 7 d.
Clofarabine was administered concurrently with CCVHD
from d 1 to 5. Plasma and dialysate specimens were
collected for determination of clofarabine levels at h0,
h3, h7, and h24. After chemotherapy, intermittent
dialysis was resumed at 3 sessions per week.
The average peak of clofarabine was 2.72  .81 mM.
There was no accumulation between d 1 and 5.
The average dialysis clearance was 1.39  .26 L/h/m2,
which is about 15% of the clearance in patients
without renal failure. Drug removal appeared to
be mainly due to hemoﬁltration.
Clofarabine administration is
possible in the setting of ESRD,
but may carry signiﬁcant risk.
[35] Prospective study that enrolled 19 patients eligible
for auto-HSCT with a CrCl 60 mL/min/1.73 m2.
Patients were given palifermin on d 5 through 3
and again on d þ1 through þ3 at a dose of 60
mcg/kg/d. Mel was dose escalated until
dose-limiting toxicity was reached.
Mel dose was calculated using ABW except when the
ABW was > 40% above the IBW, and then adjusted
body weight was used. Median CrCl was 42.8 mL/min
(range, 29-60). Thirteen patients had stage 3 CKD,
1 patient had stage 4 CKD, and 1 patient had stage 2 CKD.
Mel was given in doses up to and including
200 mg/m2. Three patients were enrolled at dose
level 4, 200 mg/m2, and 1 death occurred due to
multiorgan failure as a result of multiple grade 4
toxicities and grade 3 infections. Another patient
in level 4 developed grade 3 dose-limiting toxicities
and dose escalation was stopped. No dose-limiting
toxicities were observed at dose level 3, 180 mg/m2.
The overall incidence of oral mucositis  3 was 53%.
Two of 4 patients who received 180 mg/m2 showed
complete response at 1 yr.
Mel can be safely and effectively
increased up to 180 mg/m2 in
patients with CrCl 60 mL/min.
Oral mucositis may be controlled
with palifermin.
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[36] Phase I-II study that included 10 patients in the
phase I portion and 72 patients in the phase II
portion. Clofarabine 40 mg/m2 for 5 d, Mel 140
mg/m2, and alemtuzumab 20 mg/d for 5 d was
adopted as the preparative regimen before
allo-HSCT for the phase II portion.
Median GFR at admission was 96 mg/mL/1.73 m2
(range, 25-120). After the ﬁrst 24 patients
were treated at the phase II level, the
clofarabine dose was reduced to 30 mg/m2
and the infusion was lengthened from 1 to 3 h;
however, these modiﬁcations did not appear
to reduce renal toxicity. Renal deterioration
often occurred early, after 1 or 2 doses of
clofarabine and alemtuzumab and
before administration of Mel.
Grade 3-5 renal toxicity was observed in 5 of 24
patients treated at the initial phase II level
(clofarabine 40 mg/m2  5 and Mel 140 mg/m2).
Overall, 16 of 74 patients treated at the phase II
doses experienced grade 3-5 renal toxicity. Grade
1-2 elevations of creatinine were observed in an
additional 20 patients treated at this dose level.
There was a signiﬁcant correlation between
baseline GFR and renal toxicity.
Clofarabine potentially has intrinsic
nephrotoxicity, at least in
susceptible patients, such as
patients with impaired baseline
renal function and/or older adults.
[37] Report of 5 patients with profound renal
impairment, including 3 on dialysis, who
underwent HSCT. The preparative regimen
utilized consisted of Flu 24-30 mg/m2/d for
5 d, Mel 100 mg/m2, and alemtuzumab
20 mg/d for 5 d.
Doses of Mel were reduced 25% to 100 mg/m2
and Flu was reduced by 20% in 3 of the 5
patients. Estimated GFR based on the modiﬁed
MDRD for the 2 patients who were not dialysis
dependent was 30 mL/min and 28 mL/min
before transplantation.
Frequent neurologic complications were observed,
which were attributable to tacrolimus, prompting
early discontinuation of tacrolimus in 4 of 5
patients and contributing to death in 2 of 5 patients.
Renal function remained stable in nondialysis
patients and 1 patient on hemodialysis became
dialysis independent 6 mo after HCT. One patient
developed PRES months after transplantation
without exposure to calcineurin inhibitors, possibly
as a late result of neurotoxicity from Flu.
Flu dosing may need to be
minimized or avoided in patients
with renal impairment to reduce
the potential for neurologic
toxicity.
[38] Prospective trial that included 26 patients
with recurrent CD20þ B cell lymphoid
malignancies who received Flu 30 mg/m2
daily for 4 d, Cy 750 mg/m2 daily for 3 d,
and rituximab 375 mg/m2 on d 13, 6, þ1,
and þ8 as a preparative regimen before
allo-HSCT. Patients receiving unrelated donor
allo-HSCT also received intravenous rabbit
ATG, total dosage of 5-7.5 mg/kg daily for 3 d.
GVHD prophylaxis consisted of tacrolimus and
i.v. mini-methotrexate (5 mg/m2 with or
without leucovorin on d þ1, þ3, and þ6). Ten
patients had chronic lymphocytic leukemia, 7
had mantle cell lymphoma, 3 had diffuse large
B cell lymphoma, 3 had follicular lymphoma,
and 3 had transformed lymphoma.
The conditioning regimen was well tolerated with
no patients developing grade III or IV mucositis and
none requiring intravenous parenteral nutrition
support. All patients engrafted and survived 100 d
after transplantation. Maximum acute GVHD
occurred in 8 patients and chronic GVHD occurred
in 6 patients.
Data supports the effectiveness of
standard rituximab dosing for
allo-HSCT. Flu/Cy/rituximab is an
effective preparative regimen for
patients with B cell lymphoid
malignancies. This regimen
appears to be safe, with a low
incidence of acute GVHD and NRM.
[39] Retrospective analysis of the effect of mildly
reduced renal function based on CrCl on outcome
after allo HSCT. Patients were classiﬁed into
group 0 (n ¼ 440, 90 mL/min/1.73 m2),
group 1 (n ¼ 56, 60-89 mL/min/1.73 m2),
or group 2 (n ¼ 11, 30-59 mL/min/1.73 m2).
67 patients were considered to have mild
impairment, whereas only 2 had a serum
creatinine > 1.2 mg/dL. In patients in whom
the CrCl was measured more than once before
HSCT, the average values were used. CrCl was
calculated from a serum sample and 24-h urine
sample, and corrected by the actual body
surface area. CrCl was also measured using
the CKD-EPI formula.
Engraftment was achieved in 92.5, 92.5, and 100%
of the patients in groups 0, 1, and 2, respectively,
P ¼ .67. There was no difference between groups
in overall survival. The incidence of NRM was
higher in group 2, although the differences were
not statistically signiﬁcant (23.7, 28.2, and 47.2%
at 3 yr, P ¼ .20).
Patients with mildly reduced
CrCl do not have worse outcomes
with HSCT.
AA indicates aplastic anemia; ABW, actual body weight; ALL, acute lymphoblastic leukemia; allo, allogeneic; AML, acute myeloid leukemia; ATG, antithymocyte globulin; auto, autologous; AUC, area under the curve; BMT, bone
marrow transplantation; Bu, busulfan; CCVHD, continuous veno-venous hemodialysis; CG, Cockcroft-Gault; CKD, chronic kidney disease; CKD-EPI, chronic kidney disease epidemiology collaboration; CML, chronic myelogenous
leukemia; CMV, cytomegalovirus; CR, complete remission; CrCl, creatinine clearance; CY, cyclophosphamide; d, day; ESRD, end-stage renal disease; FA, Fanconi anemia; F-ARA-A, 2-ﬂuoro-ara-A; Flu, ﬂudarabine; GFR,
glomerular ﬁltration rate; GVHD, graft-versus-host disease; HDT, high-dose therapy; HSCT, hematopoietic stem cell transplantation; IBW, ideal body weight; MDRD, modiﬁcation of diet in renal disease; MDS, myelodysplastic
syndrome; Mel, melphalan; NRM, nonrelapse morality; PO, per oral; PRES, posterior reversible encephalopathy syndrome; TAI, thoracoabdominal irradiation; TBI, total body irradiation; TLI, total lymph node irradiation; TRM,
treatment-related mortality.
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Appendix 2
Chemotherapy Evidence Table
Reference Agent Basis Doses Utilized Comments
[25] Alemtuzumab Report of an adult sickle cell patient who required dialysis. He received
Flu, Cy, and alemtuzumab as a preparative regimen before allo-HSCT. The
patient received daily dialysis for 6 h, 12 h after each Flu dose.
100 mg given in divided doses over
5 d
Robust immune recovery was observed in this patient.
[26] Alemtuzumab Report of a severe AA patient with renal impairment (CrCl 43 mL/min)
who received Flu, low-dose CY, and alemtuzumab as a preparative
regimen before allo-HSCT.
75 mg No dosage adjustment was utilized.
[26] Alemtuzumab Report of a dialysis-dependent patient with severe AA who received
Flu, low-dose CY, and alemtuzumab as a preparative regimen before
allo-HSCT.
60 mg No dosage adjustment was utilized.
[37] Alemtuzumab Report of 5 patients with profound renal impairment who received a
preparative regimen consisting of Flu/Mel/ATG before allo-HSCT. Three
patients were dialysis dependent. The 2 patients who were not dialysis
dependent had an estimated GFR based on the modiﬁed MDRD of
30 mL/min and 28 mL/min before transplantation.
20 mg/d for 5 d Three patients were dialysis-dependent.
Creatinine values for the remaining 2 patients
before transplantation were 1.8 mg/dL and
2.0 mg/dL.
[18] ATG (equine) Case report of a 27-yr-old patient with AA requiring dialysis who received
Mel, ATG, and TLI as a preparative regimen before allo-HSCT. The patient
was dialyzed before Mel administration and again 24 and 72 h after
administration.
15 mg/kg/d for 3 d Excretion not inﬂuenced by renal impairment.
[28] ATG (rabbit) Report of 4 patients with GFR <60 mL/min/1.73 m2 who received
Flu/TBI/ATG as a preparative regimen before allo-HSCT.
2 mg/kg/d for 4 d ATG was given before Flu was infused.
[32] ATG (rabbit) Report of a 2-yr-old patient with FA who received Flu/CY/ATG was a
preparative regimen before allo-HSCT. Before transplantation, the patient’s
estimated CrCl was 17 mL/min/1.73 m2.
5 mg/kg/d for 4 d Standard FA conditioning regimen consisted
of CY 5 mg/kg/d i.v. for 4 d, Flu 30 mg/m2/d
i.v. for 5 d, and ATG 5 mg/kg/d i.v. for 4 d.
[33] ATG Report of a 61-yr-old patient with ESRD on hemodialysis for 5 yr who
received Flu/Mel/TBI/ATG as a preparative regimen before allo-HSCT. The
patient received daily hemodialysis during the conditioning regimen.
1.24 mg/kg/d for 2 d Unclear whether equine or rabbit ATG was
utilized.
[15] Bu Case report detailing the impact of hemodialysis on the clearance of Bu in
a patient with chronic renal failure undergoing auto peripheral stem cell
transplantation. Bu doses were administered at the start of a 4-h
hemodialysis session.
.6-1.0 mg/kg every 6 h for 5 d for
patients on dialysis undergoing
auto HSCT.
This patient received oral Bu.
[11] Bu Report of 6 patients, with multiple myeloma and chronic renal insufﬁciency
(serum creatinine >3.0 mg/dL), including 4 patients on dialysis, who received
high-dose Bu and Cy followed by auto-HSCT. Patients who were
dialysis-dependent were dialyzed before the ﬁrst dose of Cy and again at 24
and 48 h after completion of the second dose.
1 mg/kg PO every 6 h for 16 doses Oral formulation only.
[14] Bu Report of 6 multiple myeloma patients who received Bu/Mel before auto-HSCT.
Five of the 6 patients had renal failure with a median CrCl of 27 mL/h, range
5-34 mL/h. One patient was dialysis dependent requiring dialysis 3 times per
wk. Hemodialysis was performed 2 h after melphalan infusion.
12 mg/kg Unclear what the schedule or formulation
of Bu was.
[34] Clofarabine Case report of an ALL patient with ESRD, requiring dialysis, who received
clofarabine with CVVHD. Clofarabine was administered concurrently with
CCVHD from d 1 to d 5.
40 mg/m2/d for 4 d Clearance was reduced compared with
patients without renal impairment, but the
patient did not experience major toxicity.
[36] Clofarabine Phase II trial that included 72 patients received clofarabine, Mel, and
alemtuzumab before allo-HSCT. Median GFR at admission was
96 mg/mL/1.73 m2 (range, 25-120).
30-40 mg/m2/d for 4 d Signiﬁcant renal toxicity occurred, particularly
in elderly patients and patients with baseline
impaired renal function.
[11] Cy Report of 6 patients with multiple myeloma and chronic renal insufﬁciency
(serum creatinine >3.0 mg/dL), including 4 patients on dialysis, who received
high-dose Bu and Cy followed by auto-HSCT. Patients who were dialysis
dependent were dialyzed before the ﬁrst Cy dose and again at 24 and 48 h
after completion of the second dose.
60 mg/kg/d for 2 d Patients requiring renal replacement therapy
were dialyzed before the ﬁrst dose of Cy and
again at 24 and 48 h after completion of the
second dose.
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[12] Cy Case report of a 31-yr-old CML patient with chronic renal failure,
dialysis-dependent, who received CY/TBI as a preparative regimen
before allo-HSCT. Hemodialysis was performed six h after each
Cy dose over a period of 6 h. The patient also received bladder
irrigation and a continuous i.v. infusion of mesna 60 mg/kg/24 h
on d 3 and 2.
60 mg/kg/d for 2 d Hemodialysis was performed 6 h after each CY
infusion over a period of 6 h.
[13] Cy Case report of a patient with ESRD on hemodialysis who received
CY/TBI as a preparative regimen before allo-HSCT. Six-h hemodialysis
sessions were performed before CY infusion and again 14 h after the
end of each of the 2-h CY infusions on d 6 and 5. Regular 4-h
hemodialysis sessions were resumed on d 4, then 3 times each wk
until hospital discharge.
60 mg/kg/d for 2 d ABW was used for calculating CY dose.
Hemodialysis was performed before CY and
again 14 h after the end of each 2-h CY infusion.
[17] Cy Case report of a 4.5-yr-old boy with FA who received CY/TAI as a
preparative regimen before allo-HSCT. The patient’s serum creatinine
before transplantation was 278 mM.
20 mg/kg Unclear whether this was a single dose.
[25] Cy Report of an adult sickle-cell patient who required dialysis. He received
Flu, Cy, and alemtuzumab as a preparative regimen before allo-HSCT.
The patient was dialyzed daily for six h, 12 h after each Flu dose.
500 mg/m2 given daily for 4 d The patient developed symptomatic heart
failure 4 mo after transplantation, which may
have been due to Cy toxicity.
[26] Cy Report of a severe AA patient who was dialysis dependent and received
CY/ATG as a preparative regimen before allo-HSCT. The patient’s CrCl
was 11 mL/min at time of BMT.
87.5 mg/kg Usual dose 200 mg/kg, reduced for creatinine
clearance.
[26] Cy Report of a severe AA patient who received Flu, low-dose CY, and
alemtuzumab as a preparative regimen before allo-HSCT. The patient’s
CrCl was 43 mL/min at time of BMT.
300 mg/m2 No dosage adjustment was utilized.
[26] Cy Report of a severe AA patient who received Flu, low-dose CY, and
alemtuzumab as a preparative regimen before allo-HSCT. The patient’s
CrCl was 20 mL/min at time of BMT.
10 mg/kg given daily for 4 d No dosage adjustment was utilized.
[32] Cy Report of a 2-yr-old patient with FAwho received Flu/CY/ATG was a
preparative regimen before allo-HSCT. The patient’s CrCl was CrCl was
17 mL/min/1.73 m2 at the time of transplantation.
3.75 mg/kg/d for 4 d Standard FA conditioning regimen consisted
of CY 5 mg/kg/d i.v. for 4 d, Flu 30 mg/m2/d
i.v. for 5 d, and ATG 5 mg/kg/d i.v. for 4 d.
[25] Flu Report of an adult sickle-cell patient who required dialysis. He received
Flu, Cy, and alemtuzumab as a preparative regimen before allo-HSCT.
The patient received a 20% dose reduction and dosing was followed
by daily dialysis for six h, 12 h after each Flu dose.
24 mg/m2 given daily for 4 d Flu was dose-reduced by 20%. Nearly identical
Flu drug exposure to patients with normal
renal function was achieved. Dialysis was
performed for six h, 12 h after each Flu dose.
[26] Flu Report of 2 severe AA patients who received Flu, low-dose CY, and
alemtuzumab as a preparative regimen before allo-HSCT. Patient 1
had a CrCl of 43 mL/min, while the second patient had a CrCl of 20
mL/min at time of BMT.
30 mg/d given daily for 4 d 50% dosage reduction was utilized for both
patients.
[28] Flu Report of 13 patients with GFR <60 mL/min/1.73 m2 who were not
dialysis-dependent and received Flu/TBI or Flu/TBI/ATG as a preparative
regimen before allo-HSCT.
30 mg/m2 daily for 3 d These patients had only mildly reduced renal
function compared with controls, estimated
GFR range, 35-59 mL/min/1.73 m2.
[27] Flu Report of a 5-yr-old patient with FA and renal impairment (CrCl 22 mL/min)
who received Flu/TAI as a preparative regimen before allo-HSCT.
15 mg/m2 daily for 3 d Creatinine clearance was 22 mL/min before
transplantation.
[30] Flu Study of 141 patients with reduced GFR who received Flu/Mel or Flu/Mel/ATG
preparative regimens before allo-HSCT. A subgroup of patients had baseline
GFR <60 mL/min. This subgroup had a median GFR of 56 (range, 39-77).
25-30 mg/m2 for 4-5 d Unclear how the Flu dose was selected given
the range reported.
[31] Flu Case report of a patient with non-Hodgkin lymphoma who was dialysis
dependent and received Flu/Mel as a preparative regimen before auto-HSCT.
6 mg/m2/d for 4 d 75% dosage reduction was utilized. Dialysis
schedule during preparative regimen administration
not reported.
(continued on next page)
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Appendix 2
(continued )
Reference Agent Basis Doses Utilized Comments
[32] Flu Report of a 2-yr-old patient with FA who received Flu/CY/ATG was a preparative
regimen before allo-HSCT. The patient’s CrCl was CrCl was 17 mL/min/1.73 m2
at the time of transplantation.
15 mg/kg/d i.v. for 3 d Standard FA conditioning regimen consisted
of CY 5 mg/kg/d i.v. for 4 d, Flu 30 mg/m2/d
i.v. for 5 d, and ATG 5 mg/kg/d i.v. for 4 d.
[33] Flu Report of a 61-yr-old patient with ESRD, on dialysis for 5 yr, who received
Flu/Mel/TBI/ATG as a preparative regimen before allo-HSCT. During the
preparative regimen, the patient received daily hemodialysis for
volume control.
15 mg/m2/d for 5 d Represents a 50% dosage reduction.
[37] Flu Report of 5 patients with profound renal impairment, including 3 on
dialysis, who received a preparative regimen consisting of Flu/Mel/ATG
before allo-HSCT. Estimated GFR based on the modiﬁed MDRD for the 2
patients who were not dialysis dependent was 30 mL/min and 28 mL/min
before transplantation.
24-30 mg/m2/d for 5 d Flu was reduced by 20% for the 3 patients receiving
dialysis. Dialysis schedules during preparative
regimen dosing not reported.
[24] Mel Report of 4 pediatric patients with decreased nGFR (<60 mL/min/1.73 m2)
who received dose-escalating Mel, thiotepa, and vincristine as a preparative
regimen before auto-HSCT.
135-180 mg/m2 Patients 1 and 2 received Mel 150 mg/m2,
patient 3 received Mel 180 mg/m2, and patient
4 received Mel 135 mg/m2.
[14] Mel Report of 4 multiple myeloma patients who received Bu/Mel before
auto-HSCT. Impaired renal function was deﬁned as CrCl <40 mL/h. Median
CrCl was 27 mL/h, range, 5-34 mL/h.
120 mg/m2 Patients who received this dose had a CrCl
ranging from 28-34 mL/hr.
[14] Mel Report of 2 patients with severe renal impairment (CrCl 20 mL/hr),
including 1 patient on hemodialysis, who received a single dose of
80 mg/m2 before auto-HSCT.
80 mg/m2 Outcomes were similar to 4 other multiple
myeloma patients who received Mel
120 mg/m2 þ Bu 12 mg/kg. Dialysis schedule
during Mel administration not reported.
[10] Mel Prospective pharmacokinetic analysis of 20 multiple myeloma patients
who received this regimen. Six patients had severe renal insufﬁciency
(CrCl <40 mL/min), including 5 patients on chronic hemodialysis.
100 mg/m2 given for 2 d Other studies have shown this regimen to
be too toxic in patients with renal impairment.
Dialysis schedule during Mel administration not
reported.
[16] Mel Prospective study of 81 multiple myeloma patients with renal failure
(deﬁned as creatinine >176.8 mmoL/L) who underwent HSCT. Patients on
dialysis who received Mel were dialyzed before the dose and again 24-48 h
after stem cell infusion.
140 mg/m2
70-100 mg/m2 for patients with low
serum albumin or high risk of TRM
Initial dosing was 100 mg/m2 given for 2 d, but
this regimen was found to be too toxic.
[20] Mel Prospective study of 59 dialysis-dependent patients who underwent
auto-HSCT. Dialysis was performed 24-36 h after Mel dosing.
140 mg/m2 Dose was reduced from 200 mg/m2 because of
excessive toxicity.
[22] Mel Prospective trial of 137 multiple myeloma patients who received HDT
followed by auto stem cell transplantation. Twenty-nine patients had
renal failure (CrCl <60 mL/min) including 8 patients who were
hemodialysis dependent.
Reduce the dose from 200 mg/m2 to
either 140 mg/m2 or 100 mg/m2
for 2 d.
Does not detail their criteria for dose
modiﬁcation in their patient population.
Dialysis schedule during Mel administration
not reported.
[23] Mel Matched-pairs analysis that included 17 patients with multiple myeloma
and light-chain amyloidosis on chronic dialysis.
100 mg/m2 This reduced dose appears to be equally effective
to 200 mg/m2 administered to patients with
normal renal function. Dialysis schedule not
reported.
[30] Mel Study of 141 patients with reduced GFR who received
Flu/Mel or Flu/Mel/ATG preparative regimens before allo-HSCT. A
subgroup of patients had baseline GFR
<60 mL/min. This subgroup had a median GFR of 56 (range, 39-77).
100, 140, or 180 mg/m2 total dose Unclear how the Mel dose was selected, given
the range of dosages.
[31] Mel Case report of a patient with non-Hodgkin lymphoma who was
dialysis dependent and received Flu/Mel as a preparative regimen
before auto-HSCT.
100 mg/m2 A dosage reduction of approximately 33% was
utilized. Dialysis schedule during preparative
regimen administration not reported.
[35] Mel Phase I dose-escalation study of 19 patients with renal impairment
who were not dialysis dependent. Median CrCl was 42.8 mL/min
(range, 29-60 mL/min).
180 mg/m2 with palifermin Dose-limiting toxicities were observed at
200 mg/m2.
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[33] Mel Report of a 61-yr-old dialysis-dependent p
Flu/Mel/TBI/ATG as a preparative regimen b
conditioning regimen, daily hemodialysis w
Represents a 50% dosage reduction.
[37] Mel Report of 5 patients with profound renal im
who were dialysis dependent, who receive
of Flu/Mel/ATG before allo-HSCT. Estimated
patients who were not dialysis dependent
before transplantation.
[38] Rituximab Prospective study of 26 patients with B cel
received FCR as a preparative regimen befo
[29] Rituximab Retrospective review of 47 patients who re
before allo-HSCT. Patients with serum crea
[24] Thiotepa Report of 4 pediatric patients with reduced
not dialysis dependent, who received Mel,
preparative regimen before auto-HSCT.
AA indicates aplastic anemia; ABW, actual body weight; ALL, acute lymphoblastic
veno-venous hemodialysis; CML, chronic myelogenous leukemia; CrCl, creatinin
phosphamide, rituximab (FCR); Flu, ﬂudarabine; GFR, glomerular ﬁltration rate; H
PRES, posterior reversible encephalopathy syndrome; TAI, thoracoabdominal irratient with ESRD who received
efore allo-HSCT. During the
as performed for volume control.
50 mg/m2/d for 2 dpairment, including 3 patients
d a preparative regimen consisting
GFR based on the MDRD for the 2
was 30 mL/min and 28 mL/min
100 mg/m2 Represents a dosage reduction of 25%.
l lymphoid malignancies who
re allo-HSCT.
375 mg/m2 for 3 d Standard rituximab dosing is efﬁcacious in this
setting. CrCl not reported.
ceived FCR as a preparative regimen
tinine  1.6 mg/dL were excluded.
375 mg/m2 for 1 d plus 1000 mg/m2
for 3 d
Optimal rituximab dosing not clearly deﬁned
from this trial.
nGFR (<60 mL/min/1.73 m2),
thiotepa, and vincristine as a
200 mg/m2 for 3 d Patients ranged in age from 21 mo to 5 yr.
leukemia; Allo, allogeneic; ATG, antithymocyte globulin; auto, autologous; BMT, bonemarrow transplantation; Bu, busulfan; CCVHD, continuous
e clearance; CY, cyclophosphamide; d, day; ESRD, end-stage renal disease; FA, Fanconi anemia; F-ARA-A, 2-ﬂuoro-ara-A; ﬂudarabine, cyclo-
DT, high-dose therapy; HSCT, hematopoietic stem cell transplantation; MDRD, modiﬁcation of diet in renal disease; Mel, melphalan; PO, per oral,
adiation; TBI, total body irradiation; TLI, total lymph node irradiation; TRM, treatment-related mortality.
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